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Atopic dermatitis (AD) is a chronic inflammatory skin disease. Myeloproliferative neo-
plasms (MPNs) are hematopoietic malignancies caused by uncontrolled proliferation
of hematopoietic stem/progenitor cells. Recent studies have described several mutant
mice exhibiting both AD-like skin inflammation and MPN. Common pathways for skin
inflammation encompass overexpression of thymic stromal lymphopoietin and reduced
signaling of epidermal growth factor receptor in the epidermis, while overproduction
of granulocyte-colony-stimulating factor by keratinocytes and constitutive activation of
Stat5 in hematopoietic stem cells are important for the development of MPN. The murine
studies suggest the existence of a similar human disease tentatively termed as the atopic
dermatitis-myeloproliferative neoplasm syndrome.
Keywords: atopic dermatitis, myeloproliferative neoplasm, hematopoietic stem cell, mast cell, mouse models
Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease. Although the etiology of AD
is not completely understood, clinical and basic studies suggest that impaired skin barrier function
and immune dysregulation underlie the disease (1). For example, loss-of-function mutations in
the filaggrin gene (FLG) are the most well-characterized risk factor for the development of AD
(2, 3). Filaggrin plays a critical role in skin barrier function (4). Tight junctions below the stratum
corneum also contribute to skin barrier. The expression of the tight junction proteins, claudin-1 and
claudin-23, is reduced in patients with AD (5). In immunological terms, AD has been characterized
by excessive Th2 cell and eosinophilic infiltration in acute lesions and a mixed Th1 and Th2 pattern
in chronic lesions (6). Recent studies also suggest the involvement of Th17 cells in the acute but not
the chronic phase (7, 8). Additionally, the expression of genes encoding neutrophil chemoattractants
was revealed in AD lesions, consistent with increased neutrophil infiltration in the lesions (9).
Mechanistic studies of AD have been mostly conducted by mouse experiments (10, 11) despite
perceived differences in human and mouse biology (12–14). Importantly, several mutant mice
develop both AD-like skin inflammation and myeloproliferative neoplasm (MPN), suggesting the
existence of a disease tentatively termed as the atopic dermatitis-myeloproliferative neoplasm (AD-
MPN) syndrome. A majority of AD models do not develop MPN, as AD is a common disease but
MPN is a rare disease. MPNs are hematopoietic malignancies characterized by an overproduction
of any combination of white cells, red cells, and platelets. Human MPNs include polycythemia
vera, essential thrombocythemia, primary myelofibrosis, and chronic myelogenous leukemia
(15). Interestingly, pruritus is a common symptom in Philadelphia chromosome-negative MPNs.
Abbreviations:AD, atopic dermatitis; EGFR, epidermal growth factor receptor; G-CSF, granulocyte-colony-stimulating factor;
MPN, myeloproliferative neoplasm; PLC, phospholipase C; TSLP, thymic stromal lymphopoietin.
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Suggestive of the role of mast cells in both disease phenotypes,
mast cells fromMPNs release greater amounts of pruritogenic fac-
tors, such as histamine, leukotrienes, and IL-31 (16). The mutant
mice with epidermal deletion [by K5 (or K14)-Cre-mediated
deletion of a floxed gene] of JunB (transcription factor) (17),
a disintegrin and metalloproteinase 17 (ADAM17) (18, 19) or
Notch receptors/their signal transducers (20) exhibited both AD-
like skin inflammation and MPN. We recently described AD-like
dermatitis andMPN in phospholipase C (PLC)-β3-deficient mice
(21, 22). Similar skin inflammation accompanied by increased
serum IgE and IgG1 was also described with mice deficient in
SOCS7, a negative regulator of cytokine action by inhibiting tran-
scription factors Stat5 and Stat3 (23). Therefore, in these mutant
mice, AD and MPN pathologies likely develop by the shared or
overlapping molecular and cellular mechanisms.
Myeloproliferative neoplasms are caused by uncontrolled
proliferation and/or survival of hematopoietic stem/progenitor
cells (24). Mechanistically, myeloproliferation could be caused
by granulocyte-colony-stimulating factor (G-CSF) produced by
JunB-deficient keratinocytes in JunBfl/fl;K5-Cre mice (17) and
ADAM17-deficient keratinocytes in Adam17 fl/fl;K14-Cre mice
(Figure 1) (18). Consistent with the crucial role for keratinocyte-
derived G-CSF, the loss of G-CSF in vivo prevented MPN and
reduced skin inflammation in JunBfl/fl;K5-Cre mice. Transplan-
tation of bone marrow cells derived from JunBfl/fl;K5-Cre mice
failed to transfer of the MPN phenotype to WT mice. JunB is a
direct repressor ofCsf3 (gene encodingG-CSF) transcription (17).
ADAM17 cleaves membrane proteins, working as the principal
sheddase for tumor necrosis factor and several ligands of the
epidermal growth factor receptor (EGFR). ADAM17 also activates
Notch in adult epidermis. In Adam17 /  mice, impaired Notch
signaling (i.e., decreased Notch intracellular domain) resulted
in increased c-Fos recruitment to the Csf3 promoter leading
to increased Csf3 transcription, as Notch signaling antagonized
c-Fos recruitment to the Csf3 promoter (18). G-CSF might also
be involved in skin inflammation by promoting keratinocyte
proliferation (25). Consistent with the role of reduced EGFR
signaling in AD-like skin inflammation in Adam17fl/fl;K14-Cre
FIGURE 1 | Pathogenic mechanisms for the hypothetical AD-MPN
syndrome. Keratinocyte-derived TSLP (and impaired skin barrier) seems to play
a critical role in dendritic cell-dependent Th2 responses to offending allergens or
injury. Th2 cytokines predominantly cause an acute inflammation and activation
of several types of cells, including dermal fibroblasts. Th2 cytokine-stimulated
fibroblasts secrete periostin, an αv integrin-interacting matricellular protein,
which in turn stimulates keratinocytes to secrete TSLP (35). TSLP also
stimulates mast cells to secrete Th2 and other cytokines. Periostin secretion
from dermal fibroblasts depends on Th2 cytokines and mast cells, forming at
least two positive feedback loops (indicated thick and thin circular loops).
Keratinocyte-derived G-CSF is important for MPN development in certain
mutant mice. Expression of genes coding for G-CSF and TSLP is under control
of c-Fos/AP-1, which is positively regulated by EGFR and negatively regulated
by Notch signaling and JunB. The proliferative and survival properties of
hematopoietic stem cells (HSCs) are positively regulated by Stat5, whose
constitutive activation can lead to MPN. PLC-β3 negatively regulates TSLP
production in keratinocytes, periostin production in fibroblasts, and Stat5 activity
in HSCs, mast cells, and Th2 cells. DC, dendritic cell; NICD, Notch intracellular
domain; RBPj, recombination signal binding protein for immunoglobulin
kappa region.
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mice, an ADAM17-targeted EGFR ligand transforming growth
factor-α, whose expression was strongly reduced in Adam17 / 
keratinocytes, could reconstitute the skin barrier function in
Adam17 /  mice, and mice with epidermal deletion of EGFR
exhibited AD-like dermatitis just like Adam17fl/fl;K14-Cre mice
(19). Another common pathway for skin inflammation might
be overexpression of thymic stromal lymphopoietin (TSLP)
(Figure 1), an IL-7-like cytokine produced by keratinocytes (26,
27), in lesional epidermis (18, 22, 28). Notch signaling also antag-
onized c-Fos recruitment to the Tslp promoter (18). Skin-specific
overexpression of TSLP in transgenic mice resulted in the devel-
opment of eczematous lesions and elevated serum levels of IgE
(29, 30). Both spontaneous and allergen-induced dermatitis in
Plcb3 /  mice required the receptor for TSLP (31). Expression of
TSLP was extremely high in lesional epidermis of Plcb3 /  mice.
TSLP could directly activate cutaneous sensory neurons, trigger-
ing itch (32), a major symptom that impairs the quality of life in
AD patients. Mast cells, which were required for spontaneous and
allergen-induced AD models (22, 31), were increased in lesional
skin of Plcb3 /  mice due to the increased Stat5 and reduced
SHP-1 (protein tyrosine phosphatase) activities (Figure 1) (22).
PLC-β3 functions as an adaptor by directly binding to SHP-1
and Stat5, and Stat5 activity is inactivated by dephosphorylation
of Stat5–Tyr694 by SHP-1 (21, 33). Consistent with the role of
Stat5 in AD and MPN, itchy dermatitis with increased mast cells
developed in transgenicmice expressing Jak2 V617F, an activating
mutation found in many human MPN patients that also caused a
polycythemia vera-like disease in the transgenic mice (34). The
STAT5-regulatory mechanism for increased mast cells seemed
important for AD pathogenesis in human patients as well (22).
Breakdown of the same Stat5-regulatory mechanism was also
responsible for the uncontrolled growth of hematopoietic stem
cells (HSCs) in MPN in Plcb3 /  mice (21).
Are allergic diseases such as AD protective or causative for
the hematopoietic malignancies? Behind this question, there are
two hypotheses to explain positive versus negative associations
of the atopic diseases to malignancy: the “immunosurveillance”
theory proposes that the atopic inflammatory state stimulates the
immune system to eliminate the transformed cells. On the con-
trary, in the “antigenic stimulation” theory, the atopic or immune-
stimulating condition leads to randomly occurring pro-oncogenic
mutations in actively proliferating cells (36). Some prospective
cohort studies support the hypothesis that the allergic diseases
could be the risk of hematopoietic malignancies (leukemia, lym-
phoma, and myeloma), prostate cancer, and breast cancer (36–
43), suggesting that specific types of allergies might increase risks
for certain malignancies. But ovarian cancer risk was decreased
in allergic patients (38). However, a meta-analysis of several
case–control studies reported no increased risk of leukemia (44).
The hypothetical AD-MPN syndrome might have similarities
with malignancy-associated Sweet’s syndrome or acute febrile
neutrophilic dermatosis (45). Sweet’s syndrome occurs most often
associated with acute myelogenous leukemia and is characterized
by fever, neutrophilia, erythematous skin lesions, and a diffuse
infiltrate consisting predominantly of mature neutrophils (i.e.,
these skin lesions are different from typical AD lesions). Thus,
acute myelogenous leukemia-associated Sweet’s syndrome might
be an acute evolution of an insidious MPN. Moreover, some
Sweet’s syndrome patients have mutations in the PTPN6 gene
encoding SHP-1 (46) (Figure 1). Interestingly, TSLP receptor
(also known as CRLF2) overexpression has been associated with
certain subtypes of pediatric leukemia (47, 48). Therefore, it will
be interesting to investigate whether humans have an AD-MPN
syndrome.
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